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Why do proteases mess up with antigen presentation by
re-shuffling antigen sequences?
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ScienceDirectThe sequence of a large number of MHC-presented epitopes is
not present as such in the original antigen because it has been
re-shuffled by the proteasome or other proteases. Why do
proteases throw a spanner in the works of our model of antigen
tagging and immune recognition? We describe in this review
what we know about the immunological relevance of post-
translationally spliced epitopes and why proteases seem to
have a second (dark) personality, which is keen to create new
peptide bonds.
Addresses
1Max-Planck-Institute for Biophysical Chemistry, 37077 Go¨ttingen,
Germany
2Department of Chemical Immunology, Leiden University Medical
Center, NL-2333 ZA Leiden, The Netherlands
3Centre for Inflammation Biology and Cancer Immunology (CIBCI) &
Peter Gorer Department of Immunobiology, King’s College London,
SE1 1UL London, United Kingdom
Corresponding author: Mishto, Michele (michele.mishto@kcl.ac.uk)
Current Opinion in Immunology 2018, 52:81–86
This review comes from a themed issue on Antigen processing
Edited by De Libero
https://doi.org/10.1016/j.coi.2018.04.016
0952-7915/ã 2018 The Authors. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).
Introduction
Epitopes can have their sequence re-shuffled by pro-
teases, post-translationally modified, trimmed and
bended onto MHC class I (MHC-I) molecules. Trans-
formations can be so disguising that antigens might have
trouble even recognizing themselves due to these non-
canonical peptides. Nonetheless, the immune system
seems to be able to selectively identify them non-canoni-
cal epitopes and use them for patrolling the status of the
cell [1,2].
A growing number of studies about non-canonical epi-
topes has in part whipped out what we learned from
textbooks about antigen presentation. For instance,
intrinsic characteristics of non-canonical epitopes, espe-
cially of those derived from peptide splicing, force the
boundaries of our conceptualization of the immunological
self [3]. For example, a pre-requisite for streamlinedwww.sciencedirect.com CD8+ T cells patrolling by recognizing antigenic spliced
peptides is that their generation is tightly regulated.
Indeed, if an arbitrary peptide fragment were ligated to
another fragment we would likely have dramatic pro-
blems during thymocyte selection in the thymus due
to an immense variety of spliced peptides presented by
cortical and medullary thymic epithelial cells (cTECs and
mTECs, respectively) and other medullary professional
antigen presenting cells (APCs). According to the thymic
selection models [4], only a handful of thymocytes would
survive the negative selection with such an immense
antigenic peptides’ variety presented by professional
APCs. In agreement with the pre-requisite for stream-
lined patrolling by CD8+ T cells, there is a growing body
of evidence that peptide splicing — and in particular
proteasome-catalyzed peptide splicing (PCPS) — is not
a random process, and only a minor portion of the theo-
retical spliced peptide is generated and presented to T
cells. What these driving forces are, and implications they
can have on the immune response is still to be fully
understood.
The MHC-I antigen presentation pathway is on the
contrary well described (Figure 1). CD8+ T cell activity
is strongly regulated by which epitopes are presented
onto MHC-I complexes, that is, the MHC-I immuno-
peptidome. Alterations of the MHC-I immunopeptidome
affect the cytotoxic CD8+ T cell response against viruses
and the efficacy of anti-cancer immunotherapies [5,6,7].
The immunopeptidome is influenced by several factors
(see Figure 1) including antigen availability and charac-
teristics [8,9], proteasome processing [1], transport into
the endoplasmic reticulum (ER) and loading to the pep-
tide loading complex (PLC) [10], trimming by ER
amino peptidases (ERAPs) [7,11], as well as affinity to
different MHC-I allotypes’ clefts [12].
Part of the MHC-I immunopeptidome can derive from
non-canonical reading frames [13], polymorphic or
mutated sequences [2,14,15], non-coding sequences
and DRiPs [16,17], or post-translationally modified pep-
tides [18,19]. The predominant non-canonical peptide
population seems to be, however, represented by spliced
peptides. Indeed, in the MHC-I immunopeptidomes of
human EBV-immortalized B cells and primary fibroblasts
around 20–30% of peptides are produced by PCPS [20].
Although the average number of molecules of spliced
peptides bound to MHC-I complexes is smaller than that
of non-spliced peptides [20], spliced epitopes can be
presented onto MHC-I complexes in the amountCurrent Opinion in Immunology 2018, 52:81–86
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Antigen processing and presentation by MHC-I complexes to CD8+ T cells. In this pathway, the majority of the antigens are processed by
proteasome, which produces spliced and non-spliced peptides in the cytosol. Peptides are further degraded by amino-peptidases, thereby
regenerating the cellular amino acid pool. Few peptides, however, are transported into the endoplasmic reticulum (ER) through the transporters
associated with antigen processing (TAPs), which is part of the peptide-loading complex (PLC). There, peptides can be trimmed by ER-resident
aminopeptidases (ERAPs). MHC-I-peptide complexes undergo modifications, and are transported through the Golgi to the cell surface. There, they
can be recognized by the T cell receptor (TCR), and induce CD8+ T cells priming/activation.comparable to non-spliced epitopes [21]. For example,
MHC-I-bound spliced epitopes have been found to
prime a specific CD8+ T cell response during Listeria
monocytogenes infection [22]. Furthermore, a specific acti-
vation of CD8+ T cells toward spliced epitopes derived
from tumor-associated antigens is detectable in mela-
noma patients [21] and has led to a regression of the
tumor mass in a melanoma patient and a leukemia murine
model [23,24]. As a consequence, spliced peptides are
interesting novel candidates for anti-viral vaccine devel-
opment [25] and anti-cancer immunotherapies [1,26].
The molecular base of the double life of
proteasome (and other proteases?) in
permanent balance between cleavages and
ligations
How does it come, however, that the proteasome and
possibly other proteases in human cells seem to break and
build again peptides so efficiently? We already know that
PCPS efficiency is preserved along evolution [27] and that
there are factors that promote PCPS. For instance, in vitro
assays suggest that the proteasome favors the ligation of
some peptide motifs [27,28], and where the proteasomeCurrent Opinion in Immunology 2018, 52:81–86 prefers to cleave, it does not often splice [27]. However, to
understand why the proteasome catalyzes so often PCPS,
we need some information about its structure. The pro-
teasome core particle is a barrel-shaped multi-subunit
complex. In its internal cavity, it can accumulate up to
200–300 small peptides [29], or 2–3 proteins [30,31]. It has
three pairs of catalytic subunits (b1, b2, and b5). The
active site’s threonine nucleophiles face the proteasome
internal channel and are surrounded by the non-primed
and primed substrate-binding sites (Figure 2a). The sub-
strate degradation rate is driven by the proteolytic-site
activity as well as by the peptide transport along the
internal channel [29]. The catalytic subunit substitution,
which is the hallmark differentiating proteasome isoforms,
affects — at least at a quantitative level — cleavage-site
preferences and the substrate degradation rate [29,32,33].
It also impacts PCPS, although, likely, only in a substrate-
specific manner [21,27,34]. In cells, PCPS can occur via
either transpeptidation or condensation [21,35], although
the frequency of the latter mechanism still needs to be
assessed. In in vitro assays, PCPS can efficiently occur by
splicing fragments derived from the same molecule — cis
PCPS — and from different molecules — trans PCPS —www.sciencedirect.com
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Molecular base for the unexpected high frequency of peptide splicing. (a) The human 20S core particle of the proteasome is shown based on the
structure generated by [45]. The chains B, C, H, I, J, Q, R, S, Y and Z are hidden from the structure in order to see the inner proteasome cavities
with the central chamber and its two antechambers. The a and b subunits are colored in grey and blue, respectively. As an example of a catalytic
subunit, he b2 subunit is shown in pink with its active site threonine in red. (b) Proteasome-generated spliced peptides can be formed by: firstly,
cis PCPS, when the two splice-reactants derive from the same polypeptide molecule; the ligation can occur in normal order, that is, following the
orientation from N-terminus to C-terminus of the parental protein (normal cis PCPS), or in the reverse order (reverse cis PCPS); secondly, trans
PCPS, when the two splice-reactants originate from two distinct protein molecules or two distinct proteins.(Figure 2b) [27,28,36]. According to the transpeptidation
model [35], the proteasome’s catalytic N-terminal threo-
nine nucleophile breaks the peptide bond of the residue
(PSP-P1) of the protein — thereby forming an acyl-
enzyme intermediate with the N-terminal splice-reactant,
coupled to the release of the intervening sequence — and,
instead of catalyzing the canonical peptide hydrolysis, it
catalyzes the ligation between the PSP-P1 residue of the
N-terminal splice-reactant with the residue PSP-P10 of the
C-terminal splice-reactant (Figure 2b). Proteasome-medi-
ated transpeptidation can also result in isopeptide bond
formation when a lysine side chain reacts with an acyl
enzyme intermediate. Although it has also been shown
that such peptides can induce an immune response, this
process however remains to be observed in vivo [37].
Proteasome-generated sliced epitopes are however not
the only examples of spliced epitopes. Indeed, Delong
and colleagues [38] identified some hybrid insulin pep-
tides (HIPs), derived from the ligation of a fragment of
proinsulin with peptides originating from other antigens
present in the granules of the pancreatic b cells. These
trans spliced epitopes are presented by MHC-II com-
plexes, thereby triggering a specific response in CD4+ T
cells in type 1 diabetic patients [38,39]. In general,
extracellular antigens can be internalized, processed by
proteolysis in the lysosome, bind the MHC class II
molecules, and then circulate to the cell surface and backwww.sciencedirect.com to the lysosome [40]. Although the lysosomal proteases
also rely on (thio)ester intermediates, the enzyme cata-
lyzing the production of the HIPs is still unknown.
Why do proteases (frequently) behave as ligases, too? In
principle, any protease that uses a nucleophile to pro-
mote hydrolysis through an ester intermediate can cat-
alyze transpeptidation. Hence any protease could play a
role in the formation of spliced peptides. Although it is
not understood why the proteasome in particular seems
to catalyze this process so efficiently, we can speculate
on the reasons. Transpeptidation efficiency depends
highly on three factors: firstly, high concentration of
the amine nucleophile must be present in order to favor
the formation of a novel peptide-bond over hydrolysis;
secondly, the ester needs to have a sufficient lifetime in
order to allow the reaction and peptide bond formation
over hydrolysis; thirdly, the active site in which this
ester intermediate is formed must be sufficiently acces-
sible for nucleophiles to react. The proteasome struc-
ture can favor all these three conditions, as it’s a closed
barrel that could have a high local concentration of
peptide products, and use substrate-binding sites in
proximity to the proteasome’s catalytic N-terminal thre-
onine nucleophile. Another result of peptides confine-
ment in the proteasome barrel could be the fact that
trans PCPS seems to occur less frequently than cis PCPS
[27,28,36].Current Opinion in Immunology 2018, 52:81–86
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Example of zwitter peptide potentially generated from both EBV and myelin antigens. The theoretical zwitter peptide [GPR][LLLLLL] can be
generated from both, the EBV antigen LMP1 and the human myelin protein MOG, through cis peptide splicing. This zwitter peptide is predicted to
bind the HLA-B*07:02 variant with an IC50 of 58 nM, and it is one of the 13 peptides that are predicted to strongly bind to the most common
MHC-I molecules. In this analysis the binding affinity is predicted applying the SMM prediction method [46], filtered for peptides with rank  1. The
13 theoretical zwitter peptides are predicted to bind one of the following variants: HLA-A*01:01, HLA-A*02:01, HLA-B*07:02, HLA-B*08:01, or HLA-
B*40:01 (data not shown).Theoretical impact of PCPS in recognizing the
immunological self
One major feature of peptide splicing is the theoretical
increase of the number of sequences that can be derived
from the antigen pool and be allocated in the MHC-I and
MHC-II clefts. This enlargement could have implica-
tions in the recognition of the immunological self by T
cells. Indeed, it could increase the risk of mimicry, which
is the phenomenon whereby two epitopes have sequence
similarities and are recognized by the same T cell clone
[1]. In particular, we name as ‘zwitter peptide’ a peptide
that can be derived from the human self-proteome as well
as from a pathogen proteome (Figure 3). In 2012, Calis
et al. [41] investigated the sequence overlap between
human self-peptides and a large set of non-self-peptides
derived from viruses and bacteria in the context of CD8+
T cell recognition. They found that less than 1% of all
theoretical possible 9-mer non-spliced peptides derived
from pathogens have a sequence identical to the theoret-
ical human non-spliced peptides, that is, are zwitter pep-
tides. If the zwitter antigenic peptides were presented
similarly by mTECs and other professional APCs in the
medullary thymus and by dendritic cells (DCs) in the
periphery, we would expect the absence, at the periphery,
of CD8+ T-cell clones recognizing, with high affinity, the
zwitter peptides presented by DCs, because they have
been eliminated during the thymic negative selection [4].
This phenomenon could in part explain the occurrence of
holes in the T cell repertoire and in their ability to tackleCurrent Opinion in Immunology 2018, 52:81–86 viral infections [41]. On the contrary, if the zwitter anti-
genic peptides were efficiently presented by DCs and
other APCs in the periphery but not by mTECs and other
professional APCs in the thymic medulla, we would
expect at the periphery the presence of potentially auto-
reactive CD8+ T-cell clones, which could be primed and
activated by DCs and other APCs in lymph nodes during
the pathogen infection and afterwards attack human cells
and participate to in an autoimmune response.
In multiple sclerosis, for instance, myelin-reactive CD8+
T cell are theorized to mediate the cytotoxic activity
against the oligodendrocytes leading to the characteristic
de-myelination and plaque formation. Furthermore, asso-
ciations between multiple sclerosis, some MHC-I variants
(e.g. HLA-B*07) and Epstein-Barr virus (EBV) infection
have been reported, and it has been hypothesized that an
EBV infection could trigger the priming of autoreactive
CD8+ T cell clones through mimicry [42]. Using a similar
approach as Calis et al. [41], we can compare the overlap of
theoretical 9mer peptides (either spliced or non-spliced)
derived from 24 human myelin proteins (MBP, MAG,
MOG, PLP and isoforms) and from 9 EBV antigens (i.e.
LMP1, LMP2, BMLF1, BMRF1, BZLF1, BRLF1,
BNRF1, BLLF1, EBNA3). All 27 peptides theoretically
common to myelin and EBV antigens are spliced pep-
tides, since there are no identical non-spliced peptide
sequences between these two sets of antigens. Among the
27 theoretical zwitter peptides, 13 peptides are predictedwww.sciencedirect.com
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Figure 3). Of course, this preliminary computation
accounts for only the theoretical presence or absence of
a peptide in the immunopeptidome of APCs. To better
estimate the real prevalence of zwitter antigenic peptides
and their recognition by CD8+T cells, we should consider
the TCR degeneracy, the affinity/avidity of TCRs and
MHC-I-peptides, and the dynamics of the different steps
of the MHC-I antigen presentation (Figure 1) including
the, only partially described, driving forces of PCPS. This
preliminary in silico result, however, confirms that PCPS
could play a particularly relevant role in the central
tolerance, the occurrence of large holes in the T cell
repertoire, and the autoimmune response mediated by
CD8+ T cells.
Concluding remarks
The surprising evidences reported in the last years, which
suggest that MHC-I (and in part MHC-II) immunopep-
tidomes are populated by spliced peptides, need to be
confirmed by applying different approaches before under-
standing the magnitude of their immunological rele-
vance. However, the implications of peptide splicing
could exceed the edges of antigen presentation. If pep-
tide splicing were a common reaction for other proteases
rather than proteasome, we could speculate that post-
translationally spliced peptides (and why not spliced
proteins?) could be involved in other aspects of the
immune response and cell metabolism, as it has been
proved for proteasome-processed non-spliced peptides
and proteins [43,44]. If this hypothesis were correct,
peptide splicing could be a further regulatory layer in
the life of a cell and an organism.
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